Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
viramidine + pegylated interferon alfa-2b
- Development stage
- Discontinued
- Lead developer
- Valeant Pharmaceuticals
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**Viramidine + pegylated interferon alfa-2b** is a combination therapy investigated for chronic hepatitis C treatment. Viramidine (taribavirin hydrochloride) is a guanosine analog prodrug of ribavirin that is rapidly converted to ribavirin in vivo and is designed to reduce the risk of hemolytic anemia compared to ribavirin. Pegylated interferon alfa-2b is a recombinant type I interferon, pegylated to improve pharmacokinetics, that stimulates the innate antiviral immune response primarily through activation of the JAK/STAT pathway after binding to interferon alpha/beta receptors. The combination was evaluated in phase 2 and 3 clinical trials for hepatitis C virus (HCV), showing reduced anemia rates but failing non-inferiority efficacy endpoints versus standard ribavirin/PEG-IFN therapy. Both drugs act synergistically: viramidine inhibits HCV replication as ribavirin, and pegylated interferon alfa-2b induces broad immune activation against HCV[1][3][4][5].
- Other names
- viramidine + peginterferon alfa-2bviramidine + PEG-IFN alfa-2btaribavirin + pegylated interferon alfa-2b
02
Targets
PNP (Purine nucleoside phosphorylase)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on viramidine + pegylated interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on viramidine + pegylated interferon alfa-2b.